BR100 Increased By (0.44%)
BR30 Increased By (1.39%)
KSE100 Increased By (0.62%)
KSE30 Increased By (0.61%)
BECO 5.49 No Change ▼ 0.00 (0%)
BML 56.00 Decreased By ▼ -0.76 (-1.34%)
BOP 35.41 Increased By ▲ 0.29 (0.83%)
CNERGY 8.20 Increased By ▲ 0.05 (0.61%)
DCL 11.55 Increased By ▲ 0.04 (0.35%)
FCCL 58.15 Increased By ▲ 1.40 (2.47%)
FCSC 5.15 No Change ▼ 0.00 (0%)
FFL 17.90 Increased By ▲ 0.02 (0.11%)
FNEL 1.25 No Change ▼ 0.00 (0%)
HUMNL 11.10 Decreased By ▼ -0.02 (-0.18%)
KEL 8.56 Increased By ▲ 0.14 (1.66%)
KOSM 6.75 Increased By ▲ 0.17 (2.58%)
MLCF 105.65 Increased By ▲ 2.35 (2.27%)
NBP 202.10 Increased By ▲ 1.92 (0.96%)
PACE 11.28 Decreased By ▼ -0.01 (-0.09%)
PAEL 44.42 Increased By ▲ 0.95 (2.19%)
PIAHCLA 28.66 Increased By ▲ 1.17 (4.26%)
PIBTL 18.75 Increased By ▲ 1.05 (5.93%)
PPL 248.10 Increased By ▲ 3.78 (1.55%)
PRL 35.35 Decreased By ▼ -0.08 (-0.23%)
PTC 66.15 Increased By ▲ 0.80 (1.22%)
SEARL 94.95 Increased By ▲ 1.63 (1.75%)
SSGC 32.04 Decreased By ▼ -0.90 (-2.73%)
TELE 8.93 Increased By ▲ 0.02 (0.22%)
THCCL 66.65 Decreased By ▼ -0.07 (-0.1%)
TPLP 10.76 Decreased By ▼ -0.07 (-0.65%)
TREET 25.22 Increased By ▲ 0.10 (0.4%)
TRG 64.21 Decreased By ▼ -0.69 (-1.06%)
WAVES 10.85 Decreased By ▼ -0.08 (-0.73%)
WTL 1.27 Increased By ▲ 0.02 (1.6%)
World

Finland suspends use of AstraZeneca COVID-19 vaccine

  • The institute said it estimated that the investigation would take at least one week. It said earlier this week that it had received any reports of cases of blood clots among people who had taken the AstraZeneca vaccine in Finland.
Published March 19, 2021 Updated March 19, 2021 09:19pm
By

HELSINKI: Finland has suspended the use of AstraZeneca COVID-19 vaccine while it investigates two possible cases of blood clots, the Finnish Institute for Health and Welfare said on Friday.

The institute said it estimated that the investigation would take at least one week. It said earlier this week that it had received any reports of cases of blood clots among people who had taken the AstraZeneca vaccine in Finland.

Comments

Comments are closed for this article.